Current Report Filing (8-k)
September 27 2019 - 7:24AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 26, 2019
AVEO Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in its Charter)
|
|
|
|
|
Delaware
|
|
001-34655
|
|
04-3581650
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
One Broadway, 14th Floor
|
|
|
Cambridge, Massachusetts
|
|
02142
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code:
(617) 588-1960
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
Common Stock, $0.001 par value
|
|
AVEO
|
|
Nasdaq Capital Market
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Item 5.02
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers.
|
(b) Effective October 8, 2019, Nikhil Mehta, Ph.D., senior vice president of
regulatory and quality assurance of AVEO Pharmaceuticals, Inc. (the Company), will step down as an officer of the Company to pursue another opportunity.
Michael Needle, M.D., chief medical officer, and Emile Farhan, Ph.D., senior vice president of CMC and quality, will lead the efforts to complete the
preparation of a potential tivozanib New Drug Application for advanced renal cell carcinoma. Drs. Needle and Farhan successfully led the Companys efforts to prepare the marketing authorization application (MAA) supporting
EUSAs 2016 MAA submission to the European Medicines Agency, which resulted in the approval of tivozanib in 2017 as a treatment for first line advanced renal cell carcinoma in that agencys covered territories.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
AVEO Pharmaceuticals, Inc.
|
|
|
By:
|
|
/s/ Michael Bailey
|
|
|
Michael Bailey
|
|
|
President and Chief Executive Officer
|
Date: September 27, 2019
AVEO Pharmaceuticals (NASDAQ:AVEO)
Historical Stock Chart
From Mar 2024 to Apr 2024
AVEO Pharmaceuticals (NASDAQ:AVEO)
Historical Stock Chart
From Apr 2023 to Apr 2024